Evolving Minds By Pink Elephant
Evolving Minds By Pink Elephant
Podcast Description
The Evolving Minds Podcast, by Pink Elephant. Insightful conversations with the entrepreneurs, executives, and changemakers shaping the future of mental health and psychedelic medicine. From ambitious startups to established industry leaders, we spotlight the people and ideas behind the next generation of digital health, alternative therapies, and psychedelic ventures. Meet the Minds Changing the Business of Healing
Podcast Insights
Content Themes
Key topics include the intersection of entrepreneurship and mental health, the evolution of psychedelic therapy, and disruptive innovations in digital health, with episodes like 'Why Psychedelic Startups Hit a Wall?' providing in-depth explorations of challenges faced by industry pioneers.
The Evolving Minds Podcast, by Pink Elephant. Insightful conversations with the entrepreneurs, executives, and changemakers shaping the future of mental health and psychedelic medicine. From ambitious startups to established industry leaders, we spotlight the people and ideas behind the next generation of digital health, alternative therapies, and psychedelic ventures. Meet the Minds Changing the Business of Healing
In this exclusive interview, veteran biotech executive Doug Drysdale sits down with Jason Najum from Pink Elephant to discuss the strategy that steered Cybin through the 'biotech winter.' Although Doug stepped down as CEO in September 2025 and the company has since rebranded to Helus Pharma, his insights reveal the critical data-driven decisions that allowed the company to survive and evolve when dozens of competitors failed.
#Cybin #HelusPharma #Biotech #DougDrysdale #CNS #MentalHealthInnovation #Pharma
In this conversation, Doug covers:
— Why he left a 35-year career in traditional pharma after seeing psychedelics deliver ”10 times the effect size” of standard drugs.
— The reality of the ”hype cycle”: How the industry went from 90 companies to just a handful of survivors.
— Why ”Me Too” drugs failed and why you can't just run a science project — you need a commercial product.
— The debate on short-acting trips: Why the frequency of treatments matters way more than how long the session lasts.
— His contrarian take on AI: Why computers can't design these drugs yet (and why human chemistry is still winning).
— The next frontier: Treating Parkinson's, MS, and the rise of non-hallucinogenic ”psychedelic light” supplements.
Timestamps:
00:00 Intro
00:41 35 Years in the Game
01:55 The Data That Changed His Mind (10x Effect)
05:12 When Bankers Said ”No”
07:49 Killing the Supplement Division
12:07 Why You Can't Please Every Investor
18:46 The Great Industry Culling
23:15 ”Science Projects” vs. Real Products
26:07 Do Short-Acting Trips Actually Matter?
31:46 Why AI Isn't Ready Yet
34:11 Neurodegeneration & ”Psychedelic Light”
36:26 What's Next?
https://www.linkedin.com/in/dougdrysdale/
https://www.helus.com/
Like what you heard? Hit subscribe and follow us for more in-depth insights into the future of mental health — @evolving_minds_podcast
Stay tuned with our channels:
Spotify: https://open.spotify.com/show/0lOYS1R9bu7plbF65sbR5u
Apple Podcast: https://podcasts.apple.com/us/podcast/evolving-minds-by-pink-elephant/id1829115616
LinkedIn: https://www.linkedin.com/company/pink-elephant-fund/
Twitter: https://x.com/PinkElephantHQ
The Evolving Minds podcast by Pink Elephant, hosted by Jason Najum, is a series of 1-on-1 conversations with star guests who dare to build, scale, or rethink companies, policies, and protocols at the frontier of progressive mental health.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.